睿知中国医院研究地图
候选清单

正在招募胰腺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由Gansu Wuwei Tumor Hospital牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方Gansu Wuwei Tumor Hospital武威医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06840067,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Indications: patients with locally advanced or metastatic pancreatic adenocarcinoma confirmed by histopathology or cytology (stage III - IV).

    入选标准第 2 条

  3. No history of other malignant tumors (except cured skin cancer and stage 0 cervical cancer);

    入选标准第 5 条

    Patients had other malignant neoplasms (except cured skin cancer and stage 0 cervical cancer);

    排除标准第 11 条

  4. Predicted survival (after treatment) ≥3 months;

    入选标准第 9 条

  5. Liver function, kidney function and bone marrow function were basically normal (ALT and AST < 1.5 times of high normal value (ULN), bilirubin < 1.5×ULN; Adult endogenous creatinine clearance rate of 60ml/min or serum creatinine SCR≤140μmoI/L, BUN≤6.8mmol/L; Hemoglobin level >9 g/dL; White blood cell count ≥3.0*109/L; Platelet count ≥100*109/L;)

    入选标准第 6 条

  6. At least one measurable lesion was present according to RECIST version 1.1 evaluation criteria.

    入选标准第 3 条

  7. Pregnancy (confirmed by serum or urine β-HCG test) or lactation

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06840067,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years and ≤80 years;
  2. Indications: patients with locally advanced or metastatic pancreatic adenocarcinoma confirmed by histopathology or cytology (stage III - IV).
  3. At least one measurable lesion was present according to RECIST version 1.1 evaluation criteria.
  4. Suitable for one cycle of gemcitabine combined with nituzumab.
  5. No history of other malignant tumors (except cured skin cancer and stage 0 cervical cancer);
  6. Liver function, kidney function and bone marrow function were basically normal (ALT and AST < 1.5 times of high normal value (ULN), bilirubin < 1.5×ULN; Adult endogenous creatinine clearance rate of 60ml/min or serum creatinine SCR≤140μmoI/L, BUN≤6.8mmol/L; Hemoglobin level >9 g/dL; White blood cell count ≥3.0*109/L; Platelet count ≥100*109/L;)
  7. Good physical condition, i.e. ECOG (Eastern United States Oncology Collaboration Group) 0\~2; There were no complications such as severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, and severe chronic heart disease that may affect radiotherapy. Cardiac function grade 1. (According to the New York College of Cardiology Cardiac Function Scale (NYHA)
  8. Adequate functions of major organs;
  9. Predicted survival (after treatment) ≥3 months;
  10. Informed consent has been signed by the patient or his legal representative before radiotherapy.

排除标准:Exclusion Criteria:

  1. Patients who have received monoclonal antibodies, EGFR-TKI therapy, anti-angiogenic drugs, and immunosuppressants within six months.
  2. Patients with uncontrolled, cancerous pleural effusion requiring frequent drainage, pericardial effusion, or ascites (allowing for cytological confirmation of effusion), gastrointestinal bleeding, or those identified by the investigator as having a high blood risk within 14 days prior to admission.
  3. Participated in other interventional clinical trials within 30 days prior to screening.
  4. The dose limit for organs at risk cannot reach the preset safe dose limit.
  5. Being on chronic steroid hormone therapy for more than 6 months (e.g., prednisone dose > 10 mg/ day or equivalent).
  6. People who are allergic to the drugs or their ingredients used in this program.
  7. Pregnancy (confirmed by serum or urine β-HCG test) or lactation
  8. Persons with AIDS, including those who have received antiretroviral therapy; Active stage of syphilis;
  9. Accompanied by serious comorbiditions, including uncontrolled systemic or co-existing diseases (pulmonary insufficiency, cardiovascular, pulmonary, liver, kidney, diabetes, etc.), drug or alcohol abuse, dependence, addiction, and/or mental illness that prevent the successful implementation of the trial protocol;
  10. Patients with poor compliance, including those who may not be able to complete the treatment plan or receive prescribed follow-up and examination;
  11. Patients had other malignant neoplasms (except cured skin cancer and stage 0 cervical cancer);
  12. There are contraindications to radiotherapy;
  13. having no or limited capacity for civil conduct;
  14. Any medical history that, in the investigator's judgment, might interfere with the trial results or increase the patient's risk;
  15. Any condition in which the physician considers that participation in the trial is not appropriate, the physician determines that the patient will not benefit from carbon ion radiotherapy, or that there are other co-existing conditions or other factors that may affect carbon ion therapy.
  16. Inability to understand the purpose of treatment or unwillingness/inability to sign treatment consent.

引自 ClinicalTrials.gov, NCT06840067, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06840067,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06840067